Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive systemic sclerosis and penicillamine

G P Rodnan

    The Journal of Rheumatology. Supplement
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    D-penicillamine treatment reduced skin thickening in patients with systemic sclerosis. This therapy also appeared to slow visceral involvement and improve life expectancy in progressive systemic sclerosis patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities.

    Annals of internal medicine·1986
    Same author

    Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

    Arthritis and rheumatism·1986
    Same author

    Persistence of scleroderma-like phenotype in normal fibroblasts after prolonged exposure to soluble mediators from mononuclear cells.

    Arthritis and rheumatism·1986
    Same author

    The effect of D-penicillamine on pulmonary findings in systemic sclerosis.

    Arthritis and rheumatism·1985
    Same author

    Pulmonary involvement in systemic sclerosis (scleroderma).

    Arthritis and rheumatism·1985
    Same author

    Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients.

    Arthritis and rheumatism·1985
    Same journal

    GRAPPA 2019 Research Recipient Awards Report.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

    The Journal of rheumatology. Supplement·2021
    Same journal

    Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

    The Journal of rheumatology. Supplement·2021
    Same journal

    GRAPPA 2020 Update From the Education Committee.

    The Journal of rheumatology. Supplement·2021
    Same journal

    The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

    The Journal of rheumatology. Supplement·2021
    See all related articles

    Area of Science:

    • Rheumatology
    • Dermatology
    • Pharmacology

    Background:

    • Systemic sclerosis is a chronic autoimmune disease characterized by skin thickening and potential organ damage.
    • D-penicillamine is a chelating agent with potential antifibrotic properties investigated for autoimmune conditions.

    Purpose of the Study:

    • To evaluate the efficacy of D-penicillamine in reducing skin thickening in patients with progressive systemic sclerosis.
    • To assess the impact of D-penicillamine on visceral involvement and survival in this patient cohort.

    Main Methods:

    • Retrospective analysis of 26 patients with diffuse scleroderma treated with D-penicillamine.
    • Comparison of skin biopsy weights before and after therapy in a subset of patients.
    • Evaluation of disease progression and survival rates in treated versus control groups.

    Related Experiment Videos

    Main Results:

    • D-penicillamine treatment led to a reduction in skin thickening, confirmed by decreased skin biopsy weights in 7 patients.
    • Patients receiving D-penicillamine showed minimal new visceral involvement compared to controls.
    • A trend towards prolonged life expectancy was observed in the D-penicillamine group.

    Conclusions:

    • D-penicillamine demonstrates potential as a therapeutic agent for managing skin manifestations in systemic sclerosis.
    • The drug may offer benefits in slowing disease progression and improving survival in patients with diffuse scleroderma.